BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KK2269 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of KK2269\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06266299-2580@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:KK2269: Phase 1 readout est. (NCT06266299)
DESCRIPTION:KK2269\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of KK2269 in Adult Participants With Solid Tumors\nEstimated primary compl
 etion: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/kk
 2269#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06266299
URL:https://assetmemo.bio/drug/kk2269#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
